Suven Life Sciences files investigational drug

Hyderabad, Jul 12: Suven Life Sciences submitted an application with Drug Controller General of India for grant of permission to undertake Phase-1 clinical trials of their drug SUVN-502 for treatment cognitive disorders like Alzheimer's and Schizophrenia.

SUVN-502 was a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6, intended for the treatment of cognitive disorders such as Alzheimer's and Schizophrenia, according to a company release here today.

Suven was committed to neuroscience research and for development of new treatments for neurological disorders. Suven's discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches.

Suven's CNS drug discovery scientists at Hyderabad were pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, Schizophrenia, Depression, Cognitive disorders and Neurodegeneration.

Suven Life Sciences, a Hyderabad-based Life Sciences Company, is a pioneer in Contract Research And Manufacturing Services (CRAMS) since 1995, Drug Discovery and Development Support Services (DDDSS) since 2005, and Collaborative Research Partner (CRP) with global pharma majors since 2006, the release added.

UNI